# Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

> **NCT03981705** · — · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 8 (actual)

## Conditions studied

- TN ER-/PR-/HER2- Breast Cancer
- Triple Negative Breast Cancer
- HER2-positive Breast Cancer
- ERany/PRany/HER2+ Breast Cancer

## Interventions

- **RADIATION:** Standard Trimodality Breast Imaging

## Key facts

- **NCT ID:** NCT03981705
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-08
- **Primary completion:** 2024-02-19
- **Final completion:** 2024-11-26
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03981705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03981705, "Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03981705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*